Last reviewed · How we verify

Memantine (twice daily)

H. Lundbeck A/S · FDA-approved active Small molecule

Memantine (twice daily) is a NMDA receptor antagonist Small molecule drug developed by H. Lundbeck A/S. It is currently FDA-approved for Moderate to severe Alzheimer's disease, Mild to moderate Alzheimer's disease (in combination with cholinesterase inhibitors). Also known as: Lu 00-800, Ebixa ®, Ebix ®.

Memantine is an uncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor that blocks excessive glutamate signaling in the brain.

Memantine is an uncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor that blocks excessive glutamate signaling in the brain. Used for Moderate to severe Alzheimer's disease, Mild to moderate Alzheimer's disease (in combination with cholinesterase inhibitors).

At a glance

Generic nameMemantine (twice daily)
Also known asLu 00-800, Ebixa ®, Ebix ®
SponsorH. Lundbeck A/S
Drug classNMDA receptor antagonist
TargetNMDA receptor
ModalitySmall molecule
Therapeutic areaNeurology
PhaseFDA-approved

Mechanism of action

Memantine selectively blocks NMDA receptor channels in a use-dependent manner, reducing pathological calcium influx caused by chronic glutamate excitotoxicity while preserving normal synaptic transmission. This mechanism is thought to protect neurons from degeneration in neurodegenerative diseases, particularly Alzheimer's disease, by moderating overactive glutamatergic signaling without completely blocking physiological NMDA receptor function.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Memantine (twice daily)

What is Memantine (twice daily)?

Memantine (twice daily) is a NMDA receptor antagonist drug developed by H. Lundbeck A/S, indicated for Moderate to severe Alzheimer's disease, Mild to moderate Alzheimer's disease (in combination with cholinesterase inhibitors).

How does Memantine (twice daily) work?

Memantine is an uncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor that blocks excessive glutamate signaling in the brain.

What is Memantine (twice daily) used for?

Memantine (twice daily) is indicated for Moderate to severe Alzheimer's disease, Mild to moderate Alzheimer's disease (in combination with cholinesterase inhibitors).

Who makes Memantine (twice daily)?

Memantine (twice daily) is developed and marketed by H. Lundbeck A/S (see full H. Lundbeck A/S pipeline at /company/h-lundbeck-a-s).

Is Memantine (twice daily) also known as anything else?

Memantine (twice daily) is also known as Lu 00-800, Ebixa ®, Ebix ®.

What drug class is Memantine (twice daily) in?

Memantine (twice daily) belongs to the NMDA receptor antagonist class. See all NMDA receptor antagonist drugs at /class/nmda-receptor-antagonist.

What development phase is Memantine (twice daily) in?

Memantine (twice daily) is FDA-approved (marketed).

What are the side effects of Memantine (twice daily)?

Common side effects of Memantine (twice daily) include Dizziness, Headache, Constipation, Confusion, Hypertension, Fatigue.

What does Memantine (twice daily) target?

Memantine (twice daily) targets NMDA receptor and is a NMDA receptor antagonist.

Related